TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21334621

Group type: EXPERIMENTAL
Intervention: Antichlamydial treatment
Number of subjects: 600

Group type: COMPARATOR
Intervention: No antichlamydial treatment
Number of subjects: 600

Group type: COMPARATOR
Intervention: Seronegative participants who underwent seroconversion
Number of subjects: 600
Study: 19825865

Group type: EXPERIMENTAL
Intervention: Newly presented unexplained complaints (UCs)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Being male
Number of subjects: 444

Group type: COMPARATOR
Intervention: GPs' certainty about absence of serious disease
Number of subjects: 444

Group type: COMPARATOR
Intervention: Duration of complaints >4 weeks before presentation
Number of subjects: 444

Group type: COMPARATOR
Intervention: Musculoskeletal complaint at baseline
Number of subjects: 444

Group type: COMPARATOR
Intervention: Passage of time
Number of subjects: 444

Group type: COMPARATOR
Intervention: Musculoskeletal complaints
Number of subjects: 444

Group type: COMPARATOR
Intervention: Presence of psychosocial factors
Number of subjects: 444
Study: 17239430

Group type: EXPERIMENTAL
Intervention: Weekly topotecan 4.0 mg/m2 on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 63
Study: 15617914

Group type: EXPERIMENTAL
Intervention: Multifocal IOL
Number of subjects: 80

Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 80
Study: 11379679

Group type: EXPERIMENTAL
Intervention: Intravenous 30 mg ketorolac administered before tourniquet inflation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intravenous 30 mg ketorolac administered after tourniquet inflation
Number of subjects: 48
Study: 9931687

Group type: EXPERIMENTAL
Intervention: Glutamine substitution
Number of subjects: 34

Group type: COMPARATOR
Intervention: No glutamine substitution (Control)
Number of subjects: 34
Study: 7833219

Group type: EXPERIMENTAL
Intervention: L-NG-monomethyl-arginine (L-NMMA) 4 mumol min-1 for 5 min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bradykinin 10 and 100 pmol min-1 for 3 min each dose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) 2 and 5 nmol min-1 for 3 min each dose
Number of subjects: 6

Group type: COMPARATOR
Intervention: L-NMMA
Number of subjects: 6
Study: 3122983

Group type: COMPARATOR
Intervention: Double contrast barium enema examination
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Total colonoscopy
Number of subjects: 168
Study: 31714270

Group type: EXPERIMENTAL
Intervention: Intraoperative ECMO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 0

Group type: COMPARATOR
Intervention: CPB
Number of subjects: 0
Study: 30896763

Group type: EXPERIMENTAL
Intervention: Genetically lowered 25(OH)D levels
Number of subjects: 4254

Group type: EXPERIMENTAL
Intervention: Vitamin D Genetic Risk Score (VD_GRS)
Number of subjects: 4254

Group type: EXPERIMENTAL
Intervention: Genetically determined per‐SD increase for 25(OH)D
Number of subjects: 4254
Study: 28362531

Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 17
Study: 26218494

Group type: EXPERIMENTAL
Intervention: Outpatients
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Inpatients
Number of subjects: 1064
Study: 23612559

Group type: EXPERIMENTAL
Intervention: Engagement in cell phone conversations while driving
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phone conversations as a secondary task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitivity to road conditions before engaging in calls
Number of subjects: 0
Study: 21732894

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 106

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir
Number of subjects: 106
Study: 19628666

Group type: EXPERIMENTAL
Intervention: Bradykinin B(2) receptor blocker HOE‐140
Number of subjects: 9

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 9
Study: 16638295

Group type: EXPERIMENTAL
Intervention: Subglottic secretion drainage (SSD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (non-SSD)
Number of subjects: 0
Study: 15220769

Group type: EXPERIMENTAL
Intervention: Spectral Entropy (SE)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Response Entropy (RE)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: A‐Line ARX Index (AAI)
Number of subjects: 10
Study: 11292401

Group type: EXPERIMENTAL
Intervention: Attempted eyelid closure with Goldmann applanation tonometry
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Attempted eyelid closure with Tono-pen XL
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tono-pen XL
Number of subjects: 15
Study: 9432036

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow (ABM) transplantation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Blood stem cell (BSC) transplantation
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: In vitro culture
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: T-NHL
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: t(14;18)+ B-NHL
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: B-NHLs without t(14,18)
Number of subjects: 67
Study: 8845473

Group type: EXPERIMENTAL
Intervention: Etoposide phosphate (EP) at 100 mg/m2/day for 5 days
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Etoposide phosphate (EP) at 75 mg/m2/day for 5 days
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Etoposide phosphate (EP) at 50 or 75 mg/m2/day for 5 days
Number of subjects: 27
Study: 2225518

Group type: EXPERIMENTAL
Intervention: Antimony electrode (after finger calibration)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glass electrode
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Antimony electrode (beaker calibration)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glass electrode (beaker calibration)
Number of subjects: 10
Study: 667676

Group type: EXPERIMENTAL
Intervention: Fentanyl (1 microgram/kg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Alfathesin alone
Number of subjects: 53
Study: 30522048

Group type: EXPERIMENTAL
Intervention: Extended release naltrexone (XR‐NTX)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 300
Study: 28110290

Group type: EXPERIMENTAL
Intervention: Stand-alone internet-based vestibular rehabilitation (VR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internet-based VR with physiotherapeutic support ('blended care')
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25850865

Group type: EXPERIMENTAL
Intervention: Tight glycemic control with insulin (insulin titrated to maintain blood glucose between 80 and 110 mg/dL)
Number of subjects: 561

Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 561
Study: 25029368

Group type: EXPERIMENTAL
Intervention: Fasting and 2 hour post challenge plasma glucose, family history of diabetes
Number of subjects: 8400

Group type: EXPERIMENTAL
Intervention: Wrist circumference
Number of subjects: 8400

Group type: EXPERIMENTAL
Intervention: Waist/height ratio
Number of subjects: 8400

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 8400

Group type: EXPERIMENTAL
Intervention: Low education level
Number of subjects: 8400
Study: 22192068

Group type: EXPERIMENTAL
Intervention: myo-inositol 2 g b.i.d. (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo (n = 40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: myo-inositol 2 g b.i.d.
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study: 20668885

Group type: EXPERIMENTAL
Intervention: 0.9% saline in 5% dextrose at the standard maintenance rate (Group A)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: 0.18% saline in 5% dextrose at the standard maintenance rate (Group B)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: 0.18% saline in 5% dextrose at two-thirds of the standard maintenance rate (Group C)
Number of subjects: 167
Study: 17461738

Group type: COMPARATOR
Intervention: Cholinesterase inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Memantine
Number of subjects: 0
Study: 15660059

Group type: EXPERIMENTAL
Intervention: Intravenous, intraoperative unfractionated heparin
Number of subjects: 134

Group type: COMPARATOR
Intervention: Intravenous, intraoperative saline (Control)
Number of subjects: 134
Study: 11877611

Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (dalteparin: 2,500 IU for ≤70 kg and 5,000 IU for >70 kg, started perioperatively and given once daily for 4 weeks)
Number of subjects: 130

Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 130
Study: 10571698

Group type: EXPERIMENTAL
Intervention: Antithyroid treatment
Number of subjects: 13

Group type: COMPARATOR
Intervention: Diagnosis of thyrotoxicosis
Number of subjects: 13
Study: 8701511

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 50 mcg (b.i.d.)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Oral salbutamol controlled release 8 mg (b.i.d.)
Number of subjects: 59
Study: 2071282

Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no bupivacaine infiltration)
Number of subjects: 0
Study: 6866678

Group type: EXPERIMENTAL
Intervention: Re-training once every 2 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Re-training once every 4 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: No re-training
Number of subjects: 48
Study: 31655449

Group type: EXPERIMENTAL
Intervention: Homogeneous distractors moving in the same direction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heterogeneous distractors moving in randomized directions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moving target without direction change
Number of subjects: 0
Study: 28326569

Group type: EXPERIMENTAL
Intervention: Esomeprazole (20-40 mg daily)
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Laparoscopic anti-reflux surgery (LARS)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 554
Study: 25692384

Group type: EXPERIMENTAL
Intervention: Topical rapamycin gel, 0.2%, applied twice a day for 12 weeks
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Topical rapamycin treatment
Number of subjects: 6
Study: 23434908

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (12 mg of lutein and 280 mg of DHA daily)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 19681943

Group type: EXPERIMENTAL
Intervention: TiO(2) thin film modified implants
Number of subjects: 15

Group type: COMPARATOR
Intervention: Unmodified microimplants
Number of subjects: 15
Study: 19883343

Group type: EXPERIMENTAL
Intervention: Practice-nurses-led intervention for establishing a clinical trial
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Support and training for practice nurses (PNs)
Number of subjects: 59
Study: 16696748

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including occupational and physical therapy sessions, home modifications, problem-solving strategies, energy conservation, safe performance techniques, fall recovery techniques, balance and muscle strength training.
Number of subjects: 319
Study: 14980903

Group type: EXPERIMENTAL
Intervention: Almitrine (12 microg x kg(‐1) x min(‐1) for 10 min followed by 4 microg x kg(‐1) x min(‐1))
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Almitrine
Number of subjects: 18
Study: 11570838

Group type: EXPERIMENTAL
Intervention: Family Matters program
Number of subjects: 1014
Study: 1564023

Group type: EXPERIMENTAL
Intervention: Sustained-release methylphenidate (MPH)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Standard methylphenidate (MPH)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination of standard and sustained-release MPH
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3900181

Group type: EXPERIMENTAL
Intervention: High-fat (HF) diet
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet
Number of subjects: 7
Study: 31978843

Group type: EXPERIMENTAL
Intervention: PechaKucha presentation method
Number of subjects: 134

Group type: COMPARATOR
Intervention: Traditional PowerPoint presentation
Number of subjects: 134
Study: 29544062

Group type: EXPERIMENTAL
Intervention: CHO drink (75 g CHO)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CHO+PRO drink (60.5 g CHO and 14.5 g PRO)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo drink (PLA)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: All conditions (CHO, CHO+PRO, PLA)
Number of subjects: 13
Study: 26941579

Group type: EXPERIMENTAL
Intervention: Aerosol plasma coagulation (AePC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Surgical resection (SR)
Number of subjects: 34
Study: 23740619

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (Diabetes Prevention Program)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Moderate-and-steady cluster
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Modest cluster
Number of subjects: 72
Study: 22571514

Group type: EXPERIMENTAL
Intervention: Wellness intervention group
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-treatment control with release time
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-treatment control with routine duties
Number of subjects: 60
Study: 20382280

Group type: EXPERIMENTAL
Intervention: Body weight‐supported treadmill training (BWSTT) for 4 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: General exercise program (control)
Number of subjects: 18
Study: 18953465

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of saccharides
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 16148661

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg/kg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Continuous flow 50% nitrous oxide (N(2)O)
Number of subjects: 47
Study: 12511760

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Attention placebo intervention
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 123
Study: 11379469

Group type: EXPERIMENTAL
Intervention: Modified short-course chemotherapy (S: streptomycin, H: isoniazid, R: Rifampicin, Z: pyrazinamide) for 2 months followed by 6 months of thiacetazone and isoniazid (2SHRZ/6TH or 2EHRZ/6TH)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Continuation phase of thiacetazone and isoniazid
Number of subjects: 97
Study: 8862476

Group type: EXPERIMENTAL
Intervention: High-Protein (HP) breakfast
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-Fat (HF) breakfast
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) breakfast
Number of subjects: 6
Study: 1675867

Group type: EXPERIMENTAL
Intervention: xamoterol 200 mg twice daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: enalapril 2.5, 5 or 10 mg twice daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: xamoteril 200 mg twice daily
Number of subjects: 19
Study: 3885958

Group type: EXPERIMENTAL
Intervention: D-penicillamine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 30160500

Group type: EXPERIMENTAL
Intervention: Low verbal descriptor
Number of subjects: 3390

Group type: EXPERIMENTAL
Intervention: Super Low verbal descriptor
Number of subjects: 3390

Group type: EXPERIMENTAL
Intervention: No verbal descriptor
Number of subjects: 3390

Group type: EXPERIMENTAL
Intervention: Various %ABV levels
Number of subjects: 3390

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3390
Study: 26979570

Group type: EXPERIMENTAL
Intervention: Discussion group (n=1824)
Number of subjects: 3754

Group type: COMPARATOR
Intervention: Pre-/post-only group
Number of subjects: 3754

Group type: COMPARATOR
Intervention: End-of-Project group
Number of subjects: 3754
Study: 24750799

Group type: EXPERIMENTAL
Intervention: Guna‐Interleukin 4, Guna‐Interleukin 10, and Guna‐Interleukin 11 at the concentration of 10 fg/ml
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22442391

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) as a continuous variable
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Obese group (BMI≥30)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Non-obese group (BMI<30)
Number of subjects: 499
Study: 21704105

Group type: EXPERIMENTAL
Intervention: PCV13 with Infanrix hexa/Infanrix-IPV+Hib
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCV7 with Infanrix hexa/Infanrix-IPV+Hib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV13 and PCV7
Number of subjects: 0
Study: 18358689

Group type: EXPERIMENTAL
Intervention: Nebulized hydromorphone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Systemic hydromorphone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nebulized saline
Number of subjects: 20
Study: 17057556

Group type: EXPERIMENTAL
Intervention: Pain after a series of routine nursing interventions (clustered care)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Pain after a 30-minute rest period
Number of subjects: 43
Study: 12917745

Group type: EXPERIMENTAL
Intervention: Nutritional supplements for 12 months
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no nutritional supplements)
Number of subjects: 99
Study: 10919170

Group type: EXPERIMENTAL
Intervention: Red wine (30 g alcohol/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Alcoholic solution (same degree of alcohol)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Alcohol-free red wine
Number of subjects: 56
Study: 8737133

Group type: EXPERIMENTAL
Intervention: Sparfloxacin (200 mg loading dose on day 1 followed by 100 mg daily)
Number of subjects: 686

Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg orally twice daily for 10 to 14 days)
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 686

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 686
Study: 1570375

Group type: EXPERIMENTAL
Intervention: 50 mg amitriptylinoxide (AT‐NO) IV
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 50 mg amitriptylinoxide (AT‐NO) orally
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 50 mg amitriptyline (AT) IV
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Continuous therapy with AT‐NO
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Continuous therapy with AT
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Renal plasma clearance of AT‐NO
Number of subjects: 11
Study: 6363735

Group type: EXPERIMENTAL
Intervention: Stimulation of designated auriculotherapy points
Number of subjects: 36
Study: 30072277

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) postoperatively for five sessions of 30 minutes each.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (electrodes placed but device not started).
Number of subjects: 52
Study: 30078086

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baricitinib plus Methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study: 26950160

Group type: EXPERIMENTAL
Intervention: Interspersed condition (practice questions every 1-2 slides)
Number of subjects: 301

Group type: COMPARATOR
Intervention: At-the-end condition (practice questions at the end of the presentation)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Interspersed condition (practice questions throughout lectures)
Number of subjects: 301

Group type: COMPARATOR
Intervention: At-the-end condition (practice questions at the end of the lectures)
Number of subjects: 301
Study: 24826447

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline)
Number of subjects: 60
Study: 22426706

Group type: EXPERIMENTAL
Intervention: Primary care providers (PCP)
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: Patients with a PCP
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Patients without a PCP
Number of subjects: 100000
Study: 20338817

Group type: EXPERIMENTAL
Intervention: Pain quality (throbbing and itchy pain)
Number of subjects: 0
Study: 17628437

Group type: EXPERIMENTAL
Intervention: Weight management program with food provision
Number of subjects: 0
Study: 16210665

Group type: EXPERIMENTAL
Intervention: 2 g/d of fish oil
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2 g/d of soy oil
Number of subjects: 50
Study: 12358655

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.1 mg x kg(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Droperidol 0.01 mg.kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: No prophylactic antiemetic (Control group)
Number of subjects: 60
Study: 10194077

Group type: EXPERIMENTAL
Intervention: Monocomponent pertussis toxoid vaccine
Number of subjects: 781
Study: 7590425

Group type: EXPERIMENTAL
Intervention: famotidine 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: cimetidine 200 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: cimetidine 100 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 2156416

Group type: EXPERIMENTAL
Intervention: CT plus MPA
Number of subjects: 89

Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 89
Study: 6893378

Group type: EXPERIMENTAL
Intervention: Cimetidine (0.3 mg/kg i.v. bolus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secretin (3 CU/kg/h i.v. infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of cimetidine and pirenzepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secretin (10 CU/kg s.c. and 0.5 CU/kg/h i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secretin
Number of subjects: 0
Study: 31286817

Group type: EXPERIMENTAL
Intervention: Preventive health checks offered by general practitioners
Number of subjects: 549
Study: 29105631

Group type: EXPERIMENTAL
Intervention: Cosmetic cream containing 4% Saussurea lappa extract
Number of subjects: 0